RNA-Based Therapies for Cancer
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Genetics and Molecular Medicine".
Deadline for manuscript submissions: closed (1 June 2023) | Viewed by 116
Special Issue Editor
Special Issue Information
Dear Colleagues,
RNA-based therapies have reached a new zenith after the approval of mRNA-based vaccines for COVID-19 infection. However, in the case of cancer, extensive research is going on with promising results. In the last decade, a number of seminal studies deciphered the role of microRNAs (miRNAs), short interfering RNAs (siRNA), miRNA mimics, antagomir, etc. in cancer progression. Moreover, RNA-based therapy has shed light and proved that the silencing of oncogene/tumour promoter/checkpoint proteins has positive effects on chemotherapy and immunotherapy of cancer. Despite these breakthroughs, cancer therapy often reaches resistance, partly due to many unknown proteins and poorly understood pathways. This Special Issue will delve into this field of biological research and bridge the gap in our understanding of non-coding RNAs and RNA-based therapies in cancer. This Special Issue will include topics such as non-coding RNA in cancer therapy, diagnosis and prognosis, antisense oligonucleotides, mRNA and non-coding RNA in liquid biopsy, miRNA and extracellular vesicles (EVs), mRNA-based vaccine for cancer, miRNAs in chemotherapy and immunotherapy, miRNA and nanoparticles for cancer therapy, etc.
Dr. Shoib Sarwar Siddiqui
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- miRNA
- non-coding RNA
- small activating RNAs
- antisense oligonucleotides
- chemotherapy
- immunotherapy
- circulating RNA
- liquid biopsy
- short interfering RNA
- cancer
